Orforglipron significantly reduces body weight across all BMI categories in the ATTAIN-1 trial, with results presented at AACE 2026.
So the, the question we're investigating in this study is whether the use of GLP-1 receptor agonists, which is *** medication for weight loss and diabetes, um, is associated with *** lower risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results